Literature DB >> 21472331

Inhibition of tumorigenesis and invasion of hepatocellular carcinoma by siRNA-mediated silencing of the livin gene.

Hui Liu1, Shaochuang Wang, Hangyong Sun, Zeya Pan, Weiping Zhou, Mengchao Wu.   

Abstract

Livin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety of solid tumors and cancer cell lines. Livin overexpression has been reported in hepatocellular carcinoma (HCC), suggesting the biological significance of livin in HCC progression. However, the mechanisms of livin and the consequence of its down-regulation in HCC have not been fully elucidated. A small interfering RNA (siRNA) eukaryotic expression vector specific to livin was constructed by gene recombination, and the nucleic acid was sequenced. It was then transfected into the human HCC cell line SMMC-7721. RT-PCR and Western blotting were used to validate the gene-silencing efficiency of livin in SMMC-7721 cells. Stable clones were obtained by G418 screening. Using multiple cellular and molecular approaches, such as an apoptosis assay, MTT assay, flow cytometry, Western blotting and a migration assay, the effects of livin inhibition on cell growth, migration and the induction of apoptosis in SMMC-7721 cells were observed. The siRNA eukaryotic expression vector specific to livin was constructed by gene recombination, and efficiently decreased the mRNA and protein expression of livin. The targeted inhibition of livin strongly sensitized SMMC-7721 cells to pro-apoptotic stimuli, and was associated with caspase-3 activation. In addition, the MMT assay indicated that the silencing of livin inhibited the cell growth of SMMC-7721 cells by specifically inhibiting cell mitosis. The results also showed that the silencing of livin strongly reduced the invasive capacity of SMMC-7721 cells. The findings suggest that livin expression not only provides HCC cells with increased resistance to apoptotic stimuli, but also contributes significantly to the proliferation and invasive capacity of HCC cells. Inhibition of livin may be a potential targeted approach for the treatment of HCC.

Entities:  

Year:  2010        PMID: 21472331     DOI: 10.3892/mmr.2010.355

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  Overexpression of Livin promotes migration and invasion of colorectal cancer cells by induction of epithelial-mesenchymal transition via NF-κB activation.

Authors:  Yang Ge; Xiankui Cao; Dalu Wang; Wei Sun; Hongli Sun; Bing Han; Junpeng Cui; Baolin Liu
Journal:  Onco Targets Ther       Date:  2016-02-29       Impact factor: 4.147

Review 2.  Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins.

Authors:  Darren Finlay; Peter Teriete; Mitchell Vamos; Nicholas D P Cosford; Kristiina Vuori
Journal:  F1000Res       Date:  2017-04-27

3.  Copy Number Alterations of Depressed Colorectal Neoplasm Predict the Survival and Response to Oxaliplatin in Proximal Colon Cancer.

Authors:  Li-Chun Chang; Han-Mo Chiu; Bing-Ching Ho; Min-Hsuan Chen; Yin-Chen Hsu; Wei-Tzu Chiu; Kang-Yi Su; Chia-Tung Shun; Jin-Tung Liang; Sung-Liang Yu; Ming-Shiang Wu
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

4.  The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma.

Authors:  Zide Chen; Jiehua Chen; Hongyan Liu; Wei Dong; Xuan Huang; Dajun Yang; Jinlin Hou; Xiaoyong Zhang
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

5.  Inhibitor of apoptosis protein‑like protein‑2: A novel growth accelerator for breast cancer cells.

Authors:  Lin Zhu; Weihua Zhou; Xidi Zhu; Siqi Xiang; Siyuan Wang; Yingxia Peng; Bangyun Lu; Peizhi Tang; Qian Chen; Mengjuan Wu; Xia Peng; Ziyu Chen; Ziyi Sun; Kunliang Yang; Mingjun Xiang; Dandan Yu
Journal:  Oncol Rep       Date:  2018-08-03       Impact factor: 3.906

Review 6.  Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment.

Authors:  Anita Bakrania; Gang Zheng; Mamatha Bhat
Journal:  Pharmaceutics       Date:  2021-12-25       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.